High Court Passes On Lupron Labeling Suit

Law360, New York (December 9, 2013, 2:27 PM EST) -- The U.S. Supreme Court refused on Monday to hear a Nevada woman’s claims that her suit against TAP Pharmaceutical Products Inc. and Abbott Laboratories over allegedly debilitating Lupron side effects was doomed by a federal judge’s bias and exclusion of relevant evidence.

The high court’s denial of writ of certiorari means the Ninth Circuit’s May affirmation of a jury verdict against petitioner Karin Klein will stand. Klein had argued that while the drug’s side effects left her disabled, at trial U.S. District Judge Roger L. Hunt...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.